Syros Pharmaceuticals, Inc. Common Stock
SYRS
SYRS was delisted on the 19th of March, 2025.
45 hedge funds and large institutions have $205M invested in Syros Pharmaceuticals, Inc. Common Stock in 2017 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 14 increasing their positions, 8 reducing their positions, and 1 closing their positions.
700% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 1
75% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 8
31% more capital invested
Capital invested by funds: $157M → $205M (+$48.2M)
7% more funds holding
Funds holding: 42 → 45 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$2.19M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.18M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$307K |
| 4 |
State Street
Boston,
Massachusetts
|
+$193K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$172K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$2.41M |
| 2 |
Morgan Stanley
New York
|
-$247K |
| 3 |
Goldman Sachs
New York
|
-$170K |
| 4 |
WMSA
Weiss Multi-Strategy Advisers
New York
|
-$110K |
| 5 |
JP Morgan Chase
New York
|
-$104K |
SYRS Hedge Fund Activity: Q1 2017 in Review
45 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Syros Pharmaceuticals, Inc. Common Stock (SYRS) for Q1 2017, worth a combined $205M — up 31% from $157M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new SYRS positions and 1 closed out — a net gain of 7 holders — while 14 added to existing stakes and 8 trimmed.
The largest buyer was BlackRock, adding an estimated $2.19M. The largest seller was Deerfield Management, cutting an estimated $2.41M.
- 45 institutional investors held Syros Pharmaceuticals, Inc. Common Stock (SYRS) as of Q1 2017, up from 42 in Q4 2016.
- Funds reported $205M of Syros Pharmaceuticals, Inc. Common Stock stock for Q1 2017, up 31% quarter-over-quarter.
- 8 funds opened new Syros Pharmaceuticals, Inc. Common Stock positions in Q1 2017 and 1 closed out, a net change of +7 holders.
- The largest Syros Pharmaceuticals, Inc. Common Stock buyer in Q1 2017 was BlackRock, an estimated $2.19M added.
- The largest Syros Pharmaceuticals, Inc. Common Stock seller in Q1 2017 was Deerfield Management, an estimated $2.41M sold.
Based on aggregated 13F filings for Q1 2017.